期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
卷 63, 期 -, 页码 449-469出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-051821-042743
关键词
therapeutic innovation; resolution of inflammation; specialized pro-resolving lipid mediators; annexin A1 peptides
This article discusses an innovative approach based on the biology of inflammation resolution, exploring how endogenous pro-resolving peptide and lipid mediators can offer new options for the clinical management of chronic diseases. By understanding their formation, targets, and interactions, it is possible to augment or mimic pro-resolving pathways to improve patient quality of life by treating the primary cause of a disease and managing comorbidities.
Chronic diseases that affect our society are made more complex by comorbidities and are poorly managed by the current pharmacology. While all present inflammatory etiopathogeneses, there is an unmet need for better clinical management of these diseases and their multiple symptoms. We discuss here an innovative approach based on the biology of the resolution of inflammation. Studying endogenous pro-resolving peptide and lipid mediators, how they are formed, and which target they interact with, can offer innovative options through augmenting the expression or function of pro-resolving pathways or mimicking their actions with novel targeted molecules. In all cases, resolution offers innovation for the treatment of the primary cause of a given disease and/or for the management of its comorbidities, ultimately improving patient quality of life. By implementing resolution pharmacology, we harness the whole physiology of inflammation, with the potential to bring a marked change in the management of inflammatory conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据